Some tips to help get started:
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial involves patients with refractory or relapsed locally advanced or metastatic solid tumors, such as HNSCC, NSCLC, and ccRCC, evaluating the investigational drug ABBV-CLS-484, an orally bioavailable inhibitor of PTPN2 and PTPN1 that enhances immune responses, as monotherapy or in combination with PD-1 inhibitors or VEGFR TKIs.
ClinicalTrials.gov ID: NCT04777994
HealthScout AI summary: The trial involves patients with advanced solid tumors characterized by RET gene abnormalities, where TAS0953/HM06, a selective RET inhibitor targeting the RET receptor tyrosine kinase, is administered to evaluate safety, dosing, and treatment efficacy. Phase II specifically includes NSCLC patients with RET gene fusion, assessing both those previously treated with RET inhibitors and those who have exhausted existing therapies.
ClinicalTrials.gov ID: NCT04683250
HealthScout AI summary: This trial enrolls adult patients with chemo-resistant non-small cell lung cancer, head and neck squamous cell carcinoma, cervical, and uterine cancers, who express the NEO-201 antigen, to evaluate the combination of NEO-201, a monoclonal antibody targeting specific cancer cell glycans, with pembrolizumab, to potentially overcome resistance to checkpoint inhibitors.
ClinicalTrials.gov ID: NCT03476681
HealthScout AI summary: This trial targets adult patients with advanced or metastatic solid tumors having RAS, NF1, or RAF mutations, evaluating DCC-3116, an oral ULK1/2 inhibitor that blocks autophagy, both as monotherapy and in combination with trametinib, binimetinib, or sotorasib.
ClinicalTrials.gov ID: NCT04892017
HealthScout AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.
ClinicalTrials.gov ID: NCT04787042
HealthScout AI summary: This trial investigates VMD-928, a selective TrkA inhibitor, in adult patients with advanced solid tumors or lymphoma that are resistant to existing therapies, focusing on those with TrkA overexpression or NTRK1 gene fusion.
ClinicalTrials.gov ID: NCT03556228
HealthScout AI summary: This trial focuses on patients with BRAF V600 mutation-positive cancers who have previously shown clinical benefit from and are currently treated with the BRAF inhibitor dabrafenib, the MEK inhibitor trametinib, or their combination in a Novartis or GSK parent study, assessing the long-term safety of these treatments.
ClinicalTrials.gov ID: NCT03340506